Journal
CANCER COMMUNICATIONS
Volume 42, Issue 9, Pages 804-827Publisher
WILEY
DOI: 10.1002/cac2.12330
Keywords
antibody engineering; bi; trispecific killer engager; cancer immunotherapy; chimeric antigen receptor-T (CAR-T) cell; nanobody; natural killer (NK) cell; scFv
Categories
Funding
- CAMS Innovation Fund for Medical Sciences [2021-I2M-1-017]
Ask authors/readers for more resources
This review summarizes the application of antibody variable region engineering and discusses future directions for improving cancer therapies.
The efficacy and specificity of conventional monoclonal antibody (mAb) drugs in the clinic require further improvement. Currently, the development and application of novel antibody formats for improving cancer immunotherapy have attracted much attention. Variable region-retaining antibody fragments, such as antigen-binding fragment (Fab), single-chain variable fragment (scFv), bispecific antibody, and bi/trispecific cell engagers, are engineered with humanization, multivalent antibody construction, affinity optimization and antibody masking for targeting tumor cells and killer cells to improve antibody-based therapy potency, efficacy and specificity. In this review, we summarize the application of antibody variable region engineering and discuss the future direction of antibody engineering for improving cancer therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
